The INITIATE Study: Initiating Nicotine Dependence Treatment for Smokers Admitted to Emergency Departments
Launched by OTTAWA HEART INSTITUTE RESEARCH CORPORATION · Nov 13, 2019
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The INITIATE Study is a clinical trial aimed at helping smokers who visit emergency departments (ED) to quit smoking for the long term. This study is testing a special program that includes support and incentives to encourage smokers to stop using tobacco. Quitting smoking can significantly improve health and reduce the risk of diseases like heart disease, lung problems, and various cancers. With millions of smokers visiting Canadian EDs each year, this trial seeks to provide effective support in a setting where it’s often lacking.
To participate in this study, you need to be at least 18 years old and currently smoke at least five cigarettes a day. You should also be able to read and understand English or French and live in Ontario. If you join, you'll receive follow-up support over the next two years to help you stay smoke-free. This study is particularly important because it aims to make quitting easier for smokers by addressing common challenges like cost and motivation in busy healthcare environments. Your participation could contribute to improving health outcomes for many smokers in Canada.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Current daily smoker (smokes ≥ 5 cigarettes per day);
- • ≥ 18 years of age (the age of majority in Ontario);
- • For ED sites only, assigned a CTAS level of 2-5 (emergent to non-urgent);
- • Able to read and understand English or French;
- • Resides in Ontario and eligible for Ontario Health Insurance Plan (to permit linkage with administrative data housed at the Institute for Clinical Evaluative Sciences \[ICES\]);
- • Available and willing to participate in follow-up assessments over the next 24 months;
- • Has access to a telephone or computer;
- • Able to provide informed consent
- Exclusion Criteria:
- • Currently participating in this or another smoking cessation study;
- • For ED sites only, assigned a CTAS level of 1 (resuscitation - the most seriously ill patients with highest likelihood of hospital admission) or in psychiatric emergency unit;
- • Pregnant, planning to become pregnant over the next 2 years, or breastfeeding;
- • Has morbid illness which will prevent completion of 26-week follow-up (e.g., receiving palliative care);
- • In the opinion of the attending physician, manifests acute physical and/or psychiatric illness or has cognitive impairment that would preclude participation in/benefit from the intervention.
- • Scheduled for a known elected surgery, procedure, or future hospitalization during the study period.
About Ottawa Heart Institute Research Corporation
The Ottawa Heart Institute Research Corporation is a leading clinical research organization dedicated to advancing cardiovascular medicine through innovative research and clinical trials. Affiliated with the renowned University of Ottawa Heart Institute, the corporation focuses on conducting high-quality, ethically-driven studies that aim to improve patient outcomes and enhance understanding of heart-related diseases. With a commitment to collaboration and excellence, the organization engages multidisciplinary teams of researchers, healthcare professionals, and industry partners to translate scientific discoveries into effective therapies and interventions for cardiovascular health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ottawa, Ontario, Canada
Ottawa, Ontario, Canada
Ottawa, Ont', Canada
Ottawa, Ontario, Canada
Ottawa, Ontario, Canada
Patients applied
Trial Officials
Kerri-Anne Mullen, PhD
Principal Investigator
Ottawa Heart Institute Research Corporation
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials